Introduction
============

Aplastic anemia (AA) is a type of acquired bone marrow failure syndrome that is associated with a high mortality rate. AA is characterized by the destruction of hematopoietic cells by the immune system, which can lead to severe anemia and pancytopenia ([@b1-etm-0-0-7660],[@b2-etm-0-0-7660]). Bone marrow biopsy results in AA have demonstrated that the bone cavity is filled with fat cells following the destruction of hematopoietic cells. Thus, marrow fat expansion may be another pathological factor of AA ([@b3-etm-0-0-7660]). However, the mechanism underlying the increased bone fat in AA patients is currently not well understood.

Bone marrow mesenchymal stem cells (MSCs) are a group of homogeneous cells that can differentiate into adipocytes, osteoblasts, chondrocytes, tendon cells and stellate nerve cells in the appropriate microenvironment ([@b4-etm-0-0-7660]). Studies have reported that MSCs synthesize and secrete various cytokines, including interleukin (IL)-6, IL-11, granulocyte-macrophage colony-stimulating factor and stem cell factor ([@b5-etm-0-0-7660]--[@b7-etm-0-0-7660]). In addition, MSCs interact with immune cells and hematopoietic stem cells to ensure normal hematopoiesis in the bone marrow. However, in AA patients, MSCs differentiate abnormally, with induction to adipocytes but decreased differentiation in osteoblasts, resulting in the conversation of bone marrow into fat, as well as altered levels of various hormonals, including leptin ([@b5-etm-0-0-7660],[@b8-etm-0-0-7660]).

Leptin (LEP) is a circulating hormone that is mainly secreted by adipose tissues, as well as a few other tissues and cells, such as the placenta, gastric mucosa, skeletal muscle and human mammary epithelial cells ([@b9-etm-0-0-7660]--[@b11-etm-0-0-7660]). LEP functions through its interaction with the LEP receptor (LEP-R), which is expressed in several cell types of the innate and adaptive immunity systems, including MSCs, and dendritic, natural killer, T and B cells ([@b12-etm-0-0-7660]). LEP has been recognized as an important factor for modulating the immune responses, as well as bone growth.

According to previous studies, LEP signaling is involved in the differentiation of MSCs into osteoblasts or adipogenic cells ([@b13-etm-0-0-7660],[@b14-etm-0-0-7660]). A previous study reported a higher level of LEP and a lower level of LEP-R in the plasma of AA patients ([@b15-etm-0-0-7660]). Our preliminary data identified the same tendency regarding the levels of LEP and LEP-R in the bone marrow biopsy tissue ([@b16-etm-0-0-7660]). Thus, in the present study, AA model mice were established to explore the role of LEP and LEP-R in the differentiation of MSCs in AA. The results of the present study offer a new perspective for the treatment of AA.

Materials and methods
=====================

### Animals

A total of 70 BALB/c mice (male; weight, 18--25 g; age, 7--10 weeks) were obtained from the Experimental Animal Center of Hubei Province (Shiyan, China). Three model mice had infections and one had a serious visceral hemorrhage; these mice were humanely euthanized and removed from the study. Three mice (two in model group and one in control) that were still alive on day 18 were removed from the studies and they were excessive Therefore, only 63 BALB/c mice were assessed in the current study. A total of 10 C57BL/6 mice (male; weight, 25--30 g; age, 8--10 weeks) were obtained from Hunan Silaike Jingda Laboratory Animal Co., Ltd. (China). The mice were housed individually in a temperature- and light-controlled room (21--23°C; 12-h light/dark cycle) under specific pathogen-free conditions. The mice were maintained in accordance with the Guide for the Care and the Use of Laboratory Animals of the National Institutes of Health. All experiments using mice were performed according to protocols approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (Qingdao, China).

### Induction of AA model and specimen collection

The AA mouse model was developed by infusion of lymph node (LN) cells obtained from C57BL/6 mice into the BALB/c mice ([@b17-etm-0-0-7660],[@b18-etm-0-0-7660]). A total of 70 BALB/c mice were randomly divided into the control (n=7, including 1 extra mouse in case of death during the experiments) and model (n=56, including 10% extra in case of death) groups. Mice in the model group were induced into immune-mediated AA as reported ([@b19-etm-0-0-7660]). Briefly, mice were subjected to whole-body exposure to a single dose of 4 Gy at a dose rate of 0.5 Gy/min using an X-ray irradiator system in well-ventilated vinyl containers without anesthesia. After 6 h, AA was induced in the model group through intraperitoneal injection with 1×10^6^ LN cells collected from C57BL/6 donors. After X-ray exposure, the number of hematopoietic stem cells in bone marrow decreased and the immune function was abnormal; this protocol was performed as previously described ([@b20-etm-0-0-7660]). After the donor lymphocytes were injected, the immune function was disturbed, the distribution and function of T lymphocyte subgroups were abnormal, and a large number of T cells were activated which eventually induces T lymphocytes to attack hematopoietic cells, inducing AA occurred; this protocol was performed as previously described ([@b21-etm-0-0-7660]). The LN cells included thymus, inguinal and axillary LN cells, which were disaggregated, filtered through a 200-mesh nylon filter, and then washed twice with phosphate-buffered saline (PBS) and lymphocyte separation media. The control mice were sham-irradiated, and received intraperitoneal injection of PBS and lymphocyte separation media of the same volume.

Food intake and behavior of mice were observed every day after LN cell infusion. Samples were randomly harvested from the mice on days 0, 3, 6, 9, 12, 15 and 18 after LN cell infusion. In total, 8 mice from the model group and 1 from the control group were examined at each time point, resulting in a total number of 63 animals tested in the two groups. Prior to sample collection, mice were fasted for 1 h, and then blood was collected from the retro-orbital plexus under 2.5% isoflurane anesthesia, following which mice were immediately euthanized by cervical dislocation. Cardiac blood samples, as well as iliac and femur specimens that were surgically dissected, were collected for further examination. Each experiment was performed twice. The study experiments lasted for \~1 month, with a preparation period of 2 days, an experimental period of 18 days and index testing for approximately 10 days.

### Complete blood count

Routine blood tests, including white blood cell (WBC), red blood cell (RBC), hemoglobin (HB) and platelet (PLT) counts, were assayed with the blood collected from the retro-orbital plexus. An automatic biochemical analyzer (Sysmex F-820 semi-automatic blood analyzer; Sysmex Corporation, Kobe, Japan) was used for these tests, according to the manufacturer\'s protocol.

### Enzyme-linked immunosorbent assay (ELISA)

Cardiac blood was centrifuged at 1,509.3 × g for 10 min at room temperature and the serum was extracted from the upper layer. The serum concentrations of IL-2, IL-4, IL-5, interferon (IFN)-γ, LEP and LEP-R were determined by ELISA using kits from BD Biosciences (San Diego, CA, USA). Absorbance at 450 nm was measured using a Wallac1420 Victor 3 reader (PerkinElmer, Inc., Wellesley, MA, USA).

### Flow cytometry analysis of lymphocyte phenotype

Cardiac blood was used for lymphocyte phenotyping. Briefly, the samples were digested and washed twice with PBS. Next, approximately 1×10^6^ cells were incubated with 50 µl fluorescein isothiocyanate (FITC)-conjugated anti-CD4 and anti-CD8-phycoerythrin antibodies (cat. nos. 11-0341-81 and 11-0341-81, respectively; eBioscience; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 30 min. Immediately after washing with PBS, the cells were analyzed by flow cytometry using a FACS Calibur flow cytometer (BD Biosciences).

### Pathological observation of iliac bone tissue

Iliac bone tissues from AA model and control mice were fixed in 10% formalin at room temperature for 30 min. Specimens were then decalcified, dehydrated, fixed with xylene at room temperature for 1 h and embedded in paraffin. Next, the tissues were cut into sections with a thickness of 3 µm, and further deparaffinized with xylene and ethanol. Finally, the sections were stained with hematoxylin-eosin (HE), and observed under a Nikon ECLIPESEE600 light microscope and Nikon camera (Nikon Corporation, Tokyo, Japan).

### Immunohistochemical analysis

In the current study, the PV-9000 two-step immunohistochemical method was used to evaluate LEP-R level in slices of iliac bone tissue ([@b22-etm-0-0-7660]). Briefly, paraffin-embedded sections were deparaffinized and hydrated. Next, antigen retrieval was performed in 0.01 M citric acid (pH 6.0), and the sections were then incubated with a 3% H~2~O~2~ solution for 15 min at room temperature to block endogenous peroxidase activity. Subsequently, the sections were incubated with an anti-LEP-R antibody (cat. no. sc-8325; 1:150; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4°C overnight in a humid environment, followed by incubation with a horseradish peroxidase-labeled secondary antibody (cat. no. PV-9000; 1:50; OriGene Technologies, Inc., Beijing, China) at room temperature for 20 min. Then chromogenic agents from the DAB chromogenic agent kit (Wuhan Boshide Biological Engineering Co., Ltd., Wuhan, China) were added to the sections. Finally, the sections were counterstained with Harris hematoxylin, dehydrated and sealed. Positive LEP-R expression was noted when the membrane presented brown-yellow staining. Sections were observed under a light microscope, and the integral optical density (IOD) of each field was measured with Image-ProPlus analysis software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA). The mean IOD value of five fields is reported as the IOD of the section.

### MSC isolation, flow cytometry and reverse transcription- quantitative polymerase chain reaction (RT-qPCR)

Bone marrow-derived MSCs were obtained on days 0, 3, 6, 9, 12, 15 and 18 after injection of LN cells. The MSCs were isolated from the bone marrow of left and right femur specimens according to the following procedure: Briefly, the femurs were broken, and bone marrow cells were shocked several times with serum-free Dulbecco\'s modified Eagle\'s medium-low glucose (Gibco; Thermo Fisher Scientific, Inc.) to collect the bone marrow fluid. Next, the cells were mixed with a syringe needle, and the cell suspension was aspirated into a centrifuge tube with a sterile pipette and centrifuged at 2,675 × g at room temperature for 5 min, following which the supernatant was discarded. The rest of the bone marrow cell samples (1--2 ml) were diluted to 1:1 with RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and layered over Ficoll-Paque solution (Haoyang Biotechnology Co. Ltd., Tianjin, China). Cells were subsequently centrifuged at 267 × g for 10 min at room temperature. Then, they were placed in an 3 ml lymphocyte separation fluid (Haoyang Biotechnology Co. Ltd., Tianjin, China) and centrifuged at 2,675 × g at room temperature for 5 min. The milky white layer at the junction of the separator and the cell suspension was obtained as it contained the mononuclear cells. PBS was added to the mononuclear cells, which were then centrifugation at 267 × g for 10 min at room temperature, and then they were washed twice with PBS. As MSCs adhere *in vitro*, RPMI-1640 medium was completely replaced and non-adherent cells, which were not considered to be MSCs, were removed after 3 days. When 80--85% confluence was reached, the adherent cells were detached by treatment with 0.125% trypsin and 0.1% EDTA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and replanted at a 1:2 dilution under the same culture conditions. At passage 4, adherent cells were identified by surface markers, using PE-conjugated CD29 (cat. no. 12-0291), CD44 (cat. no. 12-0441), CD34 (cat. no. 12-0349) and CD45 (cat. no. 12-0451) monoclonal antibodies (all 1:100; eBioscience; Thermo Fisher Scientific, Inc.) that were incubated for 30 min at room temperature in the dark; cells were then analyzed using a FACScan flow cytometer (BD Biosciences).

Subsequent to 4--5 passages, the MSCs were detached, and total RNA was extracted with the RNeasy Mini kit (Qiagen) according to the manufacturer\'s protocol. Prior to processing, RNA samples were treated with DNase I. Next, qPCR was performed using an ABI PRISM 7700 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The concentration of RNA was measured by a spectrophotometer. Reverse transcription was performed using cDNA First Chain Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 1 cycle of 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 30 sec and 60°C for 30 sec. The data was analyzed with 2^−ΔΔCt^ ([@b23-etm-0-0-7660]). The primers used for β-actin, LEP, LEP-R, CCAAT/enhancer-binding protein (C/EBP)α, peroxisome proliferator-activated receptor γ (PPARγ) and runt-related transcription factor 2 (Runx2) are listed in [Table I](#tI-etm-0-0-7660){ref-type="table"}.

### Statistical analysis

All data are expressed as the mean ± standard deviation, and were analyzed using SPSS statistical software, version 17.0 (SPSS, Inc., Chicago, IL, USA). Normal distribution and homogeneity tests were used for measurement data. The results of blood routine tests, serum concentrations (IL-2, IL-4, IL-5, IFN-γ, LEP and LEP-R), lymphocyte phenotype, LEP-R expression in iliac bone marrow and MSC-associated genes (LEP, LEP-R, C/EBPα, PPARγ and Runx2) were compared between the control and model groups using analysis of variance (parametric) or Kruskal-Wallis test (non-parametric), as appropriate. Bivariate correlation analysis with Pearson\'s correlation coefficient was used to explore the direction and degree of the correlation between two factors. Comparisons with a probability value of P\<0.05 were considered to be statistically significant.

Results
=======

### General state of mice

Mice in the control group exhibited no evident decrease in activity or any other physical changes. Subsequent to injection with the LN cells, mice in the model group exhibited different degrees of weight loss, activity reduction, lassitude, piloerection, eye closure and arched backs.

### Identification of the AA model

Infusion of 1×10^6^ LN cells into BALB/c mice induced pancytopenia. On average, the number of WBCs was reduced by \~3-fold as compared with the count in control mice ([Fig. 1A](#f1-etm-0-0-7660){ref-type="fig"}). In addition, 0.5- to 3-fold reductions were observed in RBC count, HB level and PLT count in the AA model mice ([Fig. 1B-D](#f1-etm-0-0-7660){ref-type="fig"}). Analysis of the immune system function indicated that the AA model mice had significantly higher serum IFN-γ and IL-2 levels at 3, 6, 9, 12, 15 and 18 days, and IL-2 levels were also significantly higher at 0 day when compared with control mice (P\<0.05; [Fig. 1E and F](#f1-etm-0-0-7660){ref-type="fig"}). By contrast, serum IL-4 and IL-5 levels were significantly lower in AA model mice in comparison with those in untreated mice (P\<0.05; [Fig. 1G and H](#f1-etm-0-0-7660){ref-type="fig"}; [Table II](#tII-etm-0-0-7660){ref-type="table"}). The lymphocyte phenotype was also examined, and as expected, the AA mice exhibited a greater percentage of CD8^+^ T cells and reduced CD4^+^ T cells in their bone marrow ([Fig. 1I-K](#f1-etm-0-0-7660){ref-type="fig"}). Furthermore, histological examination of bone marrow samples from the AA mice at 0, 3, 6, 9, 12, 15 and 18 days ([Fig. 2B-H](#f2-etm-0-0-7660){ref-type="fig"}) demonstrated various degrees of hypocellularity and empty marrow replaced by globules of fat when compared with the normal cellularity observed in control mice ([Fig. 2A](#f2-etm-0-0-7660){ref-type="fig"}).

### Expression of serum LEP (sLEP) and serum soluble LEP-R (sLEP-R)

Following the injection of the cells, sLEP levels in mice were significantly elevated in a time-dependent manner compared with the levels in control mice, while sLEP-R levels were markedly decreased (P\<0.01; [Table III](#tIII-etm-0-0-7660){ref-type="table"}). In addition, as shown in [Table IV](#tIV-etm-0-0-7660){ref-type="table"}, the changes in sLEP and sLEP-R levels were closely associated with the changes in the levels of immune factors and various indicators in the blood (P\<0.01). Changes in sLEP levels were negatively correlated with IL-2 and IFN-γ, but positively correlated with other factors. Changes in sLEP were positively correlated with IL-2 and IFN-γ (r\>0), whereas they were negatively corrected with other factors (r\<0). By contrast, sLEP-R was negatively corrected with IL-2 and IFN-γ, and positively correlated with other factors (r\<0).

### LEP-R levels in iliac bone marrow, as measured by immunohistochemistry

Analysis of iliac bone marrow sections revealed cytoplasmic localization of LEP-R with microgranular staining. All samples examined were stained positive for LEP-R. In control mice, homogeneous immunoreactivity was observed ([Fig. 3A](#f3-etm-0-0-7660){ref-type="fig"}), whereas in the AA model mice, the LEP-R distribution was heterogeneous ([Fig. 3B-D](#f3-etm-0-0-7660){ref-type="fig"}), and LEP-R levels declined in a time-depended manner ([Fig. 3E](#f3-etm-0-0-7660){ref-type="fig"}; [Table V](#tV-etm-0-0-7660){ref-type="table"}).

### Expression levels of LEP, LEP-R, C/EBPα, C/EBPβ, PPARγ and Runx2 genes in MSCs

Bone marrow-derived MSCs were harvested at passage 4 to analyze their immunophenotype using flow cytometry. The expression of CD29 (91.98±0.07%) and CD44 (90.98±0.11%) was reported, whereas lack of CD34 (4.98±0.08%) and CD45 (5.97±0.09%) expression was observed ([Fig. 4](#f4-etm-0-0-7660){ref-type="fig"}).

Furthermore, the expression levels of LEP, LEP-R, C/EBPα, C/EBPβ, PPARγ and Runx2 genes in the bone marrow-derived MSCs were examined. The LEP and LEP-R expression levels in MSCs after infusion of LN cells are displayed in [Fig. 5A](#f5-etm-0-0-7660){ref-type="fig"}. The MSC samples from all tested AA model mice expressed high levels of LEP at 6, 9, 12, 15, 18 days compared with the control group (P\<0.01; [Table VI](#tVI-etm-0-0-7660){ref-type="table"}). In contrast, injection with the LN cells induced an evident decline in LEP-R levels at 3, 6, 9, 12, 15, 18 days compared with the control group (P\<0.01; [Table VII](#tVII-etm-0-0-7660){ref-type="table"}). In addition, the expression levels of the adipogenic genes C/EBPα, C/EBPβ and PPARγ exhibited gradual upward trends from day 6--18 ([Tables VIII](#tVIII-etm-0-0-7660){ref-type="table"}--[X](#tX-etm-0-0-7660){ref-type="table"}), while the expression of the osteogenic gene Runx2 was significantly decreased at 3, 6, 9, 12, 15, 18 days compared with the conςtrol (P\<0.01; [Fig. 5B](#f5-etm-0-0-7660){ref-type="fig"}; [Table XI](#tXI-etm-0-0-7660){ref-type="table"}). These results suggest that an increasing number of MSCs in the bone marrow were converted to fat cells.

### Correlation of LEP and LEP-R with the expression of osteogenic and adipogenic genes

Based on bivariate correlation analysis with Pearson\'s correlation coefficient, LEP levels were significantly positively correlated with the expression levels of C/EBPα, C/EBPβ and PPARγ (r\>0; P\<0.01), and negatively correlated with the expression of Runx2 (r\<0; P\<0.01). By contrast, LEP-R expression was negatively correlated with the expression of the adipogenic genes (C/EBPα, C/EBPβ and PPARγ) and positively correlated with the osteogenic gene Runx2 (P\<0.01; [Table XII](#tXII-etm-0-0-7660){ref-type="table"}).

Discussion
==========

Abnormal immunity and damage to hematopoietic stem/progenitor cells mediated by the immune system are major factors in the pathogenesis of AA ([@b24-etm-0-0-7660],[@b25-etm-0-0-7660]). In the present study, an AA animal model was established by infusion of LN cells into BALB/c mice, which was similar to graft-versus-host disease ([@b26-etm-0-0-7660]). A relatively low dosage of X-ray was used in the experiments of the present study to ensure longer survival of mice. In our preliminary experiments (data not shown), the X-ray dosages of 2.0, 4.0 and 6.0 Gy were assessed, and the dose of 4.0 Gy was finally selected since this exposure caused a notable decrease in blood routine indices, but fewer mice died from hematopenia. In further preliminary experiments, normal mice were exposed to 4.0 Gy of X-ray radiation alone, and the blood- and bone-associated indices were examined after 10 days. It was observed that the general state, blood routine results, LEP, LEP-R and bone marrow sections were not significantly different from those of the control mice (P\>0.05; data are not shown). Thus, it can be inferred that 4.0-Gy X-ray radiation may be suitable for modeling, without causing a marked number of cells to die in the bone marrow.

The typical characteristics of AA, including severe anemia and pancytopenia with decreased WBC, RBC, HB and PLT counts, were observed in the present study after LN cell infusion ([@b2-etm-0-0-7660]). Activated CD8^+^ T cells and an unbalanced CD4^+^/CD8^+^ ratio were also observed in the AA mice. As expected, different degrees of changes in IL-2, IL-4, IL-5 and IFN-γ levels were observed. These immune molecules may comprise a cytokine network that damages hematopoietic stem/progenitor cells, MSCs and angioblasts/endothelial progenitor cells ([@b4-etm-0-0-7660]). Combined with the histological alterations observed in bone sections, these results indicate that BALB/c mice infused with LN cells truly mimicked the pathological changes in AA, and are appropriate mouse models for studying the underlying mechanism.

Fat conversion of bone marrow is common in patients with AA, and fat cells are considered to fill the void left after the destruction of hematopoietic cells. As described in earlier studies, the process of adipogenesis competes with osteogenesis, resulting in the differentiation of MSCs into adipocytes over osteoblasts, with altered levels of various hormones, such as LEP ([@b27-etm-0-0-7660]--[@b29-etm-0-0-7660]). It is well known that LEP is involved in immune regulation, inflammatory responses and hematopoiesis. More specifically, LEP can affect the development and maturation of lymphocytes in bone marrow and inhibit the apoptosis of T and B lymphocytes ([@b30-etm-0-0-7660],[@b31-etm-0-0-7660]). Fernández-Riejos *et al* ([@b32-etm-0-0-7660]) and Du *et al* ([@b33-etm-0-0-7660]) reported that LEP induce the differentiation of T lymphocytes into T-helper 1 cells, which produce increased IL-2 and IFN-γ. This is consistent with the observations of the current study in AA patients, and suggests that LEP not only regulates immune responses by directly acting on mature immune cells in the peripheral blood, but also participate in the regulation of hematopoiesis by affecting lymphoid and granulocyte differentiation.

In the present study, it was observed that LEP levels were increased and LEP-R levels were decreased in the peripheral blood and bone marrow of the AA model mice. With the gradual decline of bone marrow hematopoietic capacity, LEP levels increased, and the changes in these two parameters were negatively correlated. The gradual increase in LEP levels was positively correlated with the transformation of T cells, suggesting that LEP may aggravate immune damage ([@b31-etm-0-0-7660],[@b34-etm-0-0-7660]). The increase in LEP levels and the decreased in the CD4^+^/CD8^+^ ratio were positive correlated, which also suggests that LEP increased T cell function disorder ([@b35-etm-0-0-7660]). LEP damage ([@b30-etm-0-0-7660],[@b33-etm-0-0-7660]). The increase in LEP levels and the decreased in the CD4^+^/CD8^+^ ratio were positive correlated, which also suggests that LEP increased T cell function disorder ([@b34-etm-0-0-7660]). LEP can regulate fat metabolism by promoting the osteogenic differentiation and inhibiting the adipogenic differentiation of MSCs ([@b36-etm-0-0-7660]). Theoretically, the number of fat cells in the bone marrow of the AA mice should be reduced by LEP; however, in the bone marrow microenvironment of the AA mice, LEP does not regulate the osteogenic and adipogenic differentiation of MSCs. The present study also observed that LEP-R levels decreased over time. Therefore, it can be speculated that the adipogenic differentiation of MSCs was enhanced, and that LEP-R was destroyed by immune injury or other causes, leading to increased LEP levels.

The adipogenic differentiation of MSCs is regulated by a sophisticated gene regulation mechanism. C/EBPβ, C/EBPα and PPARγ participate in a regulatory cascade during adipogenesis, and serve key roles in cell growth, differentiation and homeostasis ([@b37-etm-0-0-7660]). Furthermore, RUNX2 is a multifunctional transcription factor that controls skeletal development by regulating chondrocyte and osteoblast differentiation ([@b38-etm-0-0-7660]). In the present study, overexpression of the adipogenic genes C/EBPβ, C/EBPα and PPARγ, as well as reduced expression of RUNX2, confirmed the conversion of MSCs into fat cells.

However, the current study has certain limitations. Firstly, mice rather than rats were used in the experiments, despite the potentially better simulation of the AA pathology in rats, given certain tolerances and more tissues for testing. Secondly, the animal model was more relevant for the analysis of acute AA and may not be a study of chronic AA. To this end, a rat model will be used in future studies to detect in more detail how the MSC function on adipogenic differentiation would change via X-ray irradiation or LN infusion alone. Thirdly, the number of mice was low, which may potentially result in inaccuracies of the results. Furthermore, LEP-R levels will be artificially altered to investigate the differentiation of MSCs.

In conclusion, increased LEP levels and decreased LEP-R levels were detected in the peripheral blood and MSCs of AA mice in the present study. It is speculated that the high levels of LEP may increase the immune injury in the AA mice. In addition, the decrease in LEP-R levels may contribute to the failure of LEP to regulate the differentiation of MSCs into osteoblasts, leading to the increase of fat cells in the bone marrow of AA mice.
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![Results of blood routine examination and immune factor analyses in aplastic anemia mice and controls. (A) WBC, (B) RBC, (C) HB and (D) PLT counts. (E) IL-2, (F) IFN-γ, (G) IL-4 and (H) IL-5 serum levels were examined by ELISA. (I) CD4^+^ T cell count and (J) CD8^+^ T cell count were examined by flow cytometry. (K) The CD4^+^/CD8^+^ ratio. \*P\<0.05 and \*\*P\<0.01. WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelet; IL, interleukin; IFN, interferon.](etm-18-02-1047-g00){#f1-etm-0-0-7660}

![Histological structure of bone marrow, examined by hematoxylineosin staining in: (A) Control and aplastic anemia model mice at (B) 0 days, (C) 3 days, (D) 6 days, (E) 9 days, (F) 12 days, (G) 15 days and (H) 18 days after infusion of lymph node cells. Morphological and cytological changes were observed in mice with induced bone marrow failure.](etm-18-02-1047-g01){#f2-etm-0-0-7660}

![Immunohistochemical analysis of LEP-R levels in the bone marrow of: (A) Control mice; and AA model mice at (B) 6 days, (C) 12 days and (D) 18 days after infusion of lymph node cells. (E) Changes in LEP-R levels in the AA model mice. \*\*P\<0.01 vs. control group. LEP-R, leptin receptor; AA, aplastic anemia.](etm-18-02-1047-g02){#f3-etm-0-0-7660}

![Expression of CD29, CD44, CD34 and CD45 in mesenchymal stem cells. Protein expression levels were assessed by flow cytometry. CD, cluster of differentiation.](etm-18-02-1047-g03){#f4-etm-0-0-7660}

![(A) LEP and LEP-R levels in the mesenchymal stem cells of aplastic anemia model mice. (B) Expression levels of adipogenic and osteogenic genes. \*P\<0.05. LEP, leptin; LEP-R, leptin receptor.](etm-18-02-1047-g04){#f5-etm-0-0-7660}

###### 

Primers of reverse transcription-quantitative PCR.

  Primers   Direction   Sequence (5′-3′)           Size (bp)
  --------- ----------- -------------------------- -----------
  β-actin   F           CACGATGGAGGGGCCGGACTCATC   240
            R           TAAAGACCTCTATGCCAACACAG    
  LEP       F           ACCCTGTGCGGATTCTTGTG       147
            R           GGAGGAGACTGACTGCGTGT       
  LEP-R     F           ACATACTGTTACGGTTCTGG       175
            R           TAGCTTGTAATCACTGGGTG       
  C/EBPα    F           CCACTTGCAGTTCCAGATCG       239
            R           CCACCGACTTCTTGGCTTTG       
  C/EBPβ    F           CGCCATCGACTTCAGCCCCTAC     133
            R           CGGCTTCTTGCTCGGCTTGG       
  PPARγ     F           TTTCAAGGGTGCCAGTTTCG       169
            R           CATCTTTATTCATCAGGGAGGC     
  Runx2     F           CTCTGGCCTTCCTCTCTCAG       150
            R           GTAGGTAAAGGTGGCTGGGT       

LEP, leptin; LEP-R, leptin receptor; C/EBP, CCAAT/enhancer-binding protein; PPARγ, peroxisome proliferator-activated receptor; Runx2, runt-related transcription factor 2.

###### 

Comparison of cytokine levels (ng/ml; mean ± standard deviation) in different groups.

  Group       n   IL-2                                                         IFN-γ                                                      IL-4                                                       IL-5
  ----------- --- ------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Control     8   265.7±7.55                                                   32.12±1.83                                                 78.89±1.87                                                 105.84±3.38
  Model                                                                                                                                                                                              
    0 days    8   295.13±10.32^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   32.91±1.14                                                 67.30±1.67^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   94.26±0.89^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    3 days    8   322.56±9.74^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^    38.49±1.11^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   62.68±1.61^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   89.31±1.92^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    6 days    8   360.18±13.41^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   40.82±1.10^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   58.28±0.78^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   83.18±1.22^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    9 days    8   389.40±9.49^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^    44.10±0.76^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   54.87±1.64^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   77.48±1.58^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    12 days   8   413.17±10.14^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   45.96±3.61^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   46.00±1.76^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   66.78±1.30^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    15 days   8   451.06±12.38^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   46.14±3.04^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   35.73±2.10^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   49.48±1.43^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^
    18 days   8   464.15±16.64^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   46.17±2.13^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   35.14±3.00^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^   48.24±3.75^[a](#tfn2-etm-0-0-7660){ref-type="table-fn"}^

P\<0.01, vs. control group. LEP, leptin; LEP-R, leptin receptor; IL, interleukin; IFN-γ, interferon γ.

###### 

Comparison of sLEP and sLEP-R levels using ELISA.

  Group       n   LEP (ng/ml)                                               sLEP-R (ng/ml)
  ----------- --- --------------------------------------------------------- ---------------------------------------------------------
  Control     8   4.16±0.05                                                 7.47±0.10
  Model                                                                     
    0 days    8   4.33±0.13^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   7.04±0.10^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    3 days    8   4.62±0.17^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   6.62±0.12^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    6 days    8   5.19±0.12^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   6.25±0.13^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    9 days    8   5.37±0.09^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   5.67±0.13^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    12 days   8   5.79±0.12^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   4.98±0.16^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    15 days   8   6.30±0.06^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   4.28±0.13^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^
    18 days   8   6.33±0.29^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^   4.18±0.10^[a](#tfn3-etm-0-0-7660){ref-type="table-fn"}^

P\<0.01 vs. control group. Data are presented as mean ± standard deviation. sLEP, serum leptin; sLEP-R, serum leptin receptor.

###### 

Analysis of the association of LEP and LEP-R levels with immune and blood indices.

                  LEP      LEP-R             
  --------------- -------- -------- -------- --------
  IL-2            0.973    \<0.01   −0.974   \<0.01
  IFN-γ           0.884    \<0.01   −0.888   \<0.01
  IL-4            −0.960   \<0.01   0.983    \<0.01
  IL-5            −0.957   \<0.01   0.987    \<0.01
  CD4^+^/CD8^+^   −0.956   \<0.01   0.966    \<0.01
  WBC             −0.837   \<0.01   0.863    \<0.01
  RBC             −0.955   \<0.01   0.978    \<0.01
  HB              −0.934   \<0.01   0.959    \<0.01
  PLT             −0.824   \<0.01   0.821    \<0.01

LEP, leptin; LEP-R, leptin receptor; IL, interleukin; IFN, interferon; WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelet; CD, cluster of differentiation.

###### 

LEP-R levels in iliac bone marrow tissue.

  Group       n   LEP-R (×10^3^)
  ----------- --- ------------------------------------------------------------
  Control     6   258.85±22.15
  Model           
    0 days    6   240.28±7.39
    3 days    6   206.80±10.15^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^
    6 days    6   171.23±7.03^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^
    9 days    6   153.74±6.66^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^
    12 days   6   126.22±9.99^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^
    15 days   6   91.93±5.25^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^
    18 days   6   69.48±1.75^[a](#tfn5-etm-0-0-7660){ref-type="table-fn"}^

P\<0.01 vs. control group. Data are presented as mean ± standard deviation. LEP-R, leptin receptor.

###### 

Leptin level in bone marrow mesenchymal stem cells.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     8   1.00       --        --
  Model                                
    0 days    8   1.10       1.39      0.19
    3 days    8   1.14       2.65      0.07
    6 days    8   1.22       4.12      \<0.01
    9 days    8   1.37       8.25      \<0.01
    12 days   8   1.44       9.67      \<0.01
    15 days   8   1.61       14.72     \<0.01
    18 days   8   1.78       16.05     \<0.01

###### 

Leptin receptor level in bone marrow mesenchymal stem cells.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     8   1.00       --        --
  Model                                
    0 days    8   0.91       −2.05     0.07
    3 days    8   0.80       −5.87     \<0.01
    6 days    8   0.68       −9.80     \<0.01
    9 days    8   0.63       −9.60     \<0.01
    12 days   8   0.46       −20.95    \<0.01
    15 days   8   0.36       −24.11    \<0.01
    18 days   8   0.29       −25.96    \<0.01

###### 

CCAAT/enhancer-binding protein α gene expression level in iliac bone marrow tissue.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     6   1.00       --        --
  Model                                
    0 days    6   1.10       2.22      0.05
    3 days    6   1.15       2.81      0.02
    6 days    6   1.19       3.98      \<0.01
    9 days    6   1.39       5.64      \<0.01
    12 days   6   1.43       5.81      \<0.01
    15 days   6   1.60       9.00      \<0.01
    18 days   6   1.68       9.85      \<0.01

###### 

CCAAT/enhancer-binding protein β gene expression level in iliac bone marrow tissue.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     8   1.00       --        --
  Model                                
    0 days    8   1.10       1.58      0.15
    3 days    8   1.13       2.30      0.05
    6 days    8   1.18       2.67      0.02
    9 days    8   1.30       4.11      \<0.01
    12 days   8   1.43       5.61      \<0.01
    15 days   8   1.58       7.49      \<0.01
    18 days   8   1.67       8.88      \<0.01

###### 

Peroxisome proliferator-activated receptor γ gene expression level in iliac bone marrow tissue.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     8   1.00       --        --
  Model                                
    0 days    8   1.10       1.61      0.14
    3 days    8   1.14       1.79      0.10
    6 days    8   1.17       3.20      0.01
    9 days    8   1.37       5.26      \<0.01
    12 days   8   1.44       6.15      \<0.01
    15 days   8   1.57       9.05      \<0.01
    18 days   8   1.68       11.60     \<0.01

###### 

Runt-related transcription factor 2 gene expression level in iliac bone marrow tissue.

  Group       n   2^−ΔΔCt^   t-value   P-value
  ----------- --- ---------- --------- ---------
  Control     8   1.00       --        --
  Model                                
    0 days    8   0.91       −1.40     0.19
    3 days    8   0.81       −4.64     0.01
    6 days    8   0.66       −6.16     \<0.01
    9 days    8   0.62       −6.97     \<0.01
    12 days   8   0.48       −13.37    \<0.01
    15 days   8   0.42       −11.85    \<0.01
    18 days   8   0.33       −20.82    \<0.01

###### 

Correlation analysis of LEP and LEP-R expression on bone marrow mesenchymal stem cell surface with the expression of osteogenic and adipogenic genes.

           LEP      LEP-R             
  -------- -------- -------- -------- --------
  C/EBPα   0.780    \<0.01   −0.840   \<0.01
  C/EBPβ   0.810    \<0.01   −0.869   \<0.01
  PPARγ    0.779    \<0.01   −0.828   \<0.01
  Runx2    −0.870   \<0.01   0.947    \<0.01

LEP, leptin; LEP-R, leptin receptor; Runx2, runt-related transcription factor 2; PPARγ, peroxisome proliferator-activated receptor γ; C/EBP, CCAAT/enhancer-binding protein.
